KR100808324B1 - 아자-비시클로알킬 에테르 및 이들의 알파7-nAChR 효능제로서의 용도 - Google Patents
아자-비시클로알킬 에테르 및 이들의 알파7-nAChR 효능제로서의 용도 Download PDFInfo
- Publication number
- KR100808324B1 KR100808324B1 KR20057003665A KR20057003665A KR100808324B1 KR 100808324 B1 KR100808324 B1 KR 100808324B1 KR 20057003665 A KR20057003665 A KR 20057003665A KR 20057003665 A KR20057003665 A KR 20057003665A KR 100808324 B1 KR100808324 B1 KR 100808324B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- substituted
- halogen
- aza
- unsubstituted
- Prior art date
Links
- 0 CC1C*CC1 Chemical compound CC1C*CC1 0.000 description 2
- RHOOLJLEYYXKTK-UHFFFAOYSA-N Cc1cnc(C)nc1 Chemical compound Cc1cnc(C)nc1 RHOOLJLEYYXKTK-UHFFFAOYSA-N 0.000 description 2
- BGVTUIRPHLSMJU-UHFFFAOYSA-N Cc1nnc(C)cc1 Chemical compound Cc1nnc(C)cc1 BGVTUIRPHLSMJU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (15)
- 유리 염기 또는 산 부가염 형태의 화학식 I의 아자-비시클로알킬 유도체.<화학식 I>(상기 식에서,X는 CH2 또는 단일 결합이고;R은 (i) 할로겐; CN; 할로겐에 의해 치환될 수 있는 C1-C4알킬, C2-C4알케닐 또는 C2-C4알키닐; 할로겐에 의해 치환될 수 있는 C1-C4알콕시; 포르밀, 아세틸; C1-C3알콕시카르보닐; N,N-디-(C1-C3알킬)카르바모일; 또는 페닐 또는 페녹시로부터 선택된 하나 이상의 치환기에 의해 치환될 수 있는 C5-C10아릴 또는 헤테로-C5-C10아릴, (ii) N(R1)(R4), 또는 (iii) N(R2)(CHR3R4)이고;R1, R2 및 R3은 각각 독립적으로 H, C1-C4알킬 또는 CF3이며;R4는 할로겐; CN; 할로겐에 의해 치환될 수 있는 C1-C4알킬, C2-C4알케닐 또는 C2-C4알키닐; 할로겐에 의해 치환될 수 있는 C1-C4알콕시; 포르밀, 아세틸; C1-C3알콕시카르보닐; N,N-디-(C1-C3알킬)카르바모일; 또는 페닐 또는 페녹시로부터 선택된 하나 이상의 치환기에 의해 치환될 수 있는 C5-C10아릴 또는 헤테로-C5-C10아릴임).
- 제1항에 있어서,X가 CH2 또는 단일 결합이고;R이(a) 비치환되거나, 또는 할로겐; 시아노; 메틸렌디옥시; 비치환되거나, 또는 할로겐에 의해 일치환, 이치환 또는 삼치환된 C1-C4알킬; 또는 비치환되거나, 또는 할로겐에 의해 일치환, 이치환 또는 삼치환된 C1-C4알콕시에 의해 일치환, 이치환 또는 삼치환된 페닐,(b) 나프틸, 인다닐, 테트라리닐, 또는(c) 푸라닐, 벤조푸라닐, 이소벤조푸라닐, 벤조티에닐 또는 티에닐인유리 염기 또는 산 부가염 형태의 화학식 I의 아자-비시클로알킬 유도체.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0220581.3 | 2002-09-04 | ||
GB0220581A GB0220581D0 (en) | 2002-09-04 | 2002-09-04 | Organic Compound |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077011698A Division KR20070058027A (ko) | 2002-09-04 | 2003-09-03 | 아자-비시클로알킬 에테르 및 이들의 알파7-nAChR효능제로서의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050057126A KR20050057126A (ko) | 2005-06-16 |
KR100808324B1 true KR100808324B1 (ko) | 2008-02-27 |
Family
ID=9943515
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077011698A KR20070058027A (ko) | 2002-09-04 | 2003-09-03 | 아자-비시클로알킬 에테르 및 이들의 알파7-nAChR효능제로서의 용도 |
KR20057003665A KR100808324B1 (ko) | 2002-09-04 | 2003-09-03 | 아자-비시클로알킬 에테르 및 이들의 알파7-nAChR 효능제로서의 용도 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077011698A KR20070058027A (ko) | 2002-09-04 | 2003-09-03 | 아자-비시클로알킬 에테르 및 이들의 알파7-nAChR효능제로서의 용도 |
Country Status (26)
Country | Link |
---|---|
US (8) | US20060167002A1 (ko) |
EP (3) | EP1537104B1 (ko) |
JP (2) | JP4348422B2 (ko) |
KR (2) | KR20070058027A (ko) |
CN (1) | CN1325493C (ko) |
AT (1) | ATE448225T1 (ko) |
AU (1) | AU2003260486C1 (ko) |
BR (2) | BR122014026685B1 (ko) |
CA (1) | CA2495685C (ko) |
CY (1) | CY1109765T1 (ko) |
DE (1) | DE60330015D1 (ko) |
DK (1) | DK1537104T3 (ko) |
EC (1) | ECSP055621A (ko) |
ES (1) | ES2336099T3 (ko) |
GB (1) | GB0220581D0 (ko) |
HK (2) | HK1077822A1 (ko) |
IL (2) | IL166918A (ko) |
MX (1) | MXPA05002546A (ko) |
NO (1) | NO331556B1 (ko) |
NZ (1) | NZ538534A (ko) |
PL (1) | PL209425B1 (ko) |
PT (1) | PT1537104E (ko) |
RU (1) | RU2352569C2 (ko) |
SI (1) | SI1537104T1 (ko) |
WO (1) | WO2004022556A1 (ko) |
ZA (1) | ZA200500816B (ko) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6262265A (ja) * | 1985-09-13 | 1987-03-18 | Hitachi Ltd | 復水器自動検査補修システム |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
WO2005016923A1 (en) | 2003-08-13 | 2005-02-24 | Neurosearch A/S | Novel quinuclidine derivatives and their pharmaceutical use |
US7309699B2 (en) | 2003-12-22 | 2007-12-18 | Abbott Laboratories | 3-Quinuclidinyl amino-substituted biaryl derivatives |
US20050137217A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | Spirocyclic quinuclidinic ether derivatives |
US20050245531A1 (en) * | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7160876B2 (en) * | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7241773B2 (en) | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
US20050137203A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
US20050137398A1 (en) * | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
GB0415746D0 (en) * | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
BRPI0515500A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
BRPI0515489A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase |
GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
JP2008523058A (ja) * | 2004-12-10 | 2008-07-03 | アボット・ラボラトリーズ | 縮合ビシクロ複素環置換キヌクリジン誘導体 |
CN101208089A (zh) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂 |
GB0521508D0 (en) * | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525672D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525673D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
EP1987032A1 (en) | 2006-02-14 | 2008-11-05 | NeuroSearch A/S | 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives as nicotinic acetylcholine receptor agonists |
ATE455114T1 (de) * | 2006-02-16 | 2010-01-15 | Neurosearch As | Enantiomerenreine chinuclidinyloxy-pyridazine und ihre verwendung als nikotin-acetylcholin- rezeptorliganden |
US7893085B2 (en) | 2006-08-21 | 2011-02-22 | Genentech, Inc | Aza-benzothiophenyl compounds and methods of use |
RU2010107462A (ru) * | 2007-08-02 | 2011-09-10 | Таргасепт, Инк. (Us) | ЛЕЧЕНИЕ α7-СЕЛЕКТИВНЫМИ ЛИГАНДАМИ |
US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
MX2010014565A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
MX2010014559A (es) | 2008-07-01 | 2011-03-04 | Genentech Inc | Heterociclos bicíclicos sustituidos y metodos de uso. |
PT2889033T (pt) | 2008-11-19 | 2018-06-18 | Forum Pharmaceuticals Inc | Tratamento de sintomas negativos da esquizofrenia com (r)-7-cloro-n-(-quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida e sais farmacêuticos resultantes da mesma |
RU2011150248A (ru) * | 2009-05-11 | 2013-06-20 | Энвиво Фармасьютикалз, Инк. | Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы |
CN102573842A (zh) * | 2009-07-23 | 2012-07-11 | 诺瓦提斯公司 | 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途 |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
CA2776835A1 (en) | 2009-10-13 | 2011-04-21 | Msd Oss B.V. | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
EP2571874B1 (en) | 2010-05-17 | 2016-03-30 | Forum Pharmaceuticals Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
MX2013008704A (es) * | 2011-01-27 | 2013-08-21 | Novartis Ag | Uso de activadores del receptor de acetil-colina nicotinico alfa-7. |
MX2013010698A (es) | 2011-03-18 | 2014-02-17 | Novartis Ag | Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson. |
JP6263469B2 (ja) * | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法 |
AU2012324458B2 (en) * | 2011-10-20 | 2016-05-19 | Novartis Ag | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
EP2931315B1 (en) * | 2012-12-11 | 2017-11-29 | Novartis AG | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
EP3251673A1 (en) * | 2012-12-13 | 2017-12-06 | IP Gesellschaft für Management mbH | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
ES2883232T3 (es) * | 2013-01-15 | 2021-12-07 | Novartis Ag | Uso de agonistas del receptor nicotínico de acetilcolina alfa 7 |
JP6137336B2 (ja) * | 2013-01-15 | 2017-05-31 | ノバルティス アーゲー | ナルコレプシーの処置のためのアルファ7ニコチン性受容体アゴニストの使用 |
US20150313884A1 (en) * | 2013-01-15 | 2015-11-05 | Novartis Ag | Use of alpha 7 nicotinic acetylcholine receptor agonists |
KR101879919B1 (ko) * | 2013-01-15 | 2018-07-18 | 노파르티스 아게 | 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도 |
GB201301626D0 (en) | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
US20230381169A1 (en) | 2020-11-25 | 2023-11-30 | Vanda Pharmaceuticals Inc. | Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist |
WO2023213740A1 (en) * | 2022-05-05 | 2023-11-09 | Philip Morris Products S.A. | Nicotinic acetylcholine receptor ligands |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060821A1 (en) * | 2000-02-18 | 2001-08-23 | Astrazeneca Ab | Novel biarylcarboxamides |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB809574A (en) | 1956-01-26 | 1959-02-25 | Gasaccumulator Svenska Ab | Improvements in or relating to electrical signal light systems |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
DE2139107A1 (de) | 1971-08-04 | 1973-02-15 | Merck Patent Gmbh | Heterocyclisch substituierte adenosinverbindungen |
ZA848275B (en) | 1983-12-28 | 1985-08-28 | Degussa | New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring |
US4605652A (en) | 1985-02-04 | 1986-08-12 | A. H. Robins Company, Inc. | Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes |
DE3687980T2 (de) | 1986-01-07 | 1993-06-17 | Beecham Group Plc | Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen. |
KR880007433A (ko) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
ATE133415T1 (de) | 1987-04-15 | 1996-02-15 | Beecham Group Plc | Am brückenkopf substituierte azabicyclenderivate |
CA1307790C (en) | 1987-08-04 | 1992-09-22 | Ian Anthony Cliffe | Ethers |
GB8718445D0 (en) | 1987-08-04 | 1987-09-09 | Wyeth John & Brother Ltd | Pyridyl-ethers |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
DE8817121U1 (ko) | 1988-11-22 | 1993-02-04 | Boehringer Ingelheim Kg, 6507 Ingelheim, De | |
GB8829079D0 (en) | 1988-12-13 | 1989-01-25 | Beecham Group Plc | Novel compounds |
CA2002182C (en) | 1989-11-03 | 2000-06-13 | Richard J. Wurtman | Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use |
YU84791A (sh) | 1990-05-19 | 1994-06-10 | Boehringer Ingelheim Kg. | Biciklicni 1-aza-cikloalkalni |
DE4116582A1 (de) | 1990-05-19 | 1991-11-21 | Boehringer Ingelheim Kg | Bicyclische 1-aza-cycloalkane |
WO1992004333A1 (en) | 1990-08-31 | 1992-03-19 | Nippon Shinyaku Co., Ltd. | Pyrimidine derivative and medicine |
JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
US5260303A (en) | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
US5385912A (en) | 1991-03-08 | 1995-01-31 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Multicyclic tertiary amine polyaromatic squalene synthase inhibitors |
AU1752792A (en) | 1991-03-08 | 1992-10-06 | Rhone-Poulenc Rorer International (Holdings) Inc. | Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors |
JPH05310732A (ja) | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−3−カルボン酸誘導体 |
CA2093778A1 (en) | 1992-04-10 | 1993-10-11 | George R. Brown | Heterocyclic compounds |
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
AU7394394A (en) | 1992-10-13 | 1995-12-05 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors |
JPH06293768A (ja) | 1993-02-12 | 1994-10-21 | Sankyo Co Ltd | イソオキサゾールオキシ誘導体 |
AU6010594A (en) | 1993-02-12 | 1994-08-29 | Sankyo Company Limited | Isoxazoleoxy derivative |
JP3235913B2 (ja) | 1993-07-30 | 2001-12-04 | エーザイ株式会社 | アミノ安息香酸誘導体 |
JP4208267B2 (ja) | 1993-07-30 | 2009-01-14 | キヤノン株式会社 | 制御装置 |
US5998404A (en) | 1994-10-24 | 1999-12-07 | Eli Lilly And Company | Heterocyclic compounds and their use |
JPH11512443A (ja) | 1995-09-22 | 1999-10-26 | ノボ ノルディスク アクティーゼルスカブ | 新規な置換アザ環式またはアザ二環式化合物 |
SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
DE69819891T2 (de) | 1997-05-30 | 2004-08-26 | Neurosearch A/S | Spiro chinuclidin-derivate, ihre herstellung und verwendung |
AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
US6432975B1 (en) | 1998-12-11 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
CA2380072C (en) | 1999-07-28 | 2007-07-10 | John Cooke | Nicotine in therapeutic angiogenesis and vasculogenesis |
SE9903760D0 (sv) | 1999-10-18 | 1999-10-18 | Astra Ab | New compounds |
SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | Astra Ab | New use |
WO2001066546A1 (fr) | 2000-03-09 | 2001-09-13 | Mitsubishi Pharma Corporation | Composes spiro, leur procede de preparation et leur utilisation comme medicaments |
GB0010955D0 (en) | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
JP4616971B2 (ja) | 2000-07-18 | 2011-01-19 | 田辺三菱製薬株式会社 | 1−アザビシクロアルカン化合物およびその医薬用途 |
WO2002016358A2 (en) | 2000-08-18 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
AU2001284646A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
GB0021885D0 (en) | 2000-09-06 | 2000-10-18 | Fujisawa Pharmaceutical Co | New use |
PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
MXPA04003986A (es) | 2001-10-26 | 2004-07-23 | Upjohn Co | Carboxamidas hetero-biciclicas n-azabiciclico sustituidas como agonistas nachr. |
DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
DE10162375A1 (de) | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
AU2003214936A1 (en) | 2002-02-20 | 2003-09-09 | Pharmacia And Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
US20050245567A1 (en) | 2002-08-14 | 2005-11-03 | Dan Peters | Novel quinuclidine derivatives and their use |
GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
PL210065B1 (pl) | 2002-09-25 | 2011-11-30 | Memory Pharm Corp | Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków |
WO2004039321A2 (en) | 2002-10-29 | 2004-05-13 | Miicro, Inc. | Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease |
AU2003269413A1 (en) | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
AU2003269401A1 (en) | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases |
EP1562945B1 (en) | 2002-11-11 | 2006-11-15 | Neurosearch A/S | 1,4-diazabicyclo(3,2,2)nonane derivatives, preparation and therapeutical use thereof |
JP2006510662A (ja) | 2002-12-11 | 2006-03-30 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | α7ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療 |
BRPI0406834A (pt) | 2003-01-22 | 2005-12-27 | Pharmacia & Upjohn Co Llc | Tratamento de doença com agonistas totais do receptor nach alfa-7 |
WO2005013910A2 (en) | 2003-08-07 | 2005-02-17 | University Of South Florida | Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors |
JP4226981B2 (ja) | 2003-09-24 | 2009-02-18 | 三井金属鉱業株式会社 | プリント配線板の製造方法及びその製造方法で得られたプリント配線板 |
US7160876B2 (en) | 2003-12-22 | 2007-01-09 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137204A1 (en) | 2003-12-22 | 2005-06-23 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20070060588A1 (en) | 2003-12-22 | 2007-03-15 | Jianguo Ji | Fused bicycloheterocycle substituted quinuclidine derivatives |
US20050137203A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-quinuclidinyl amino-substituted biaryl derivatives |
US7655657B2 (en) | 2003-12-22 | 2010-02-02 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
US7241773B2 (en) | 2003-12-22 | 2007-07-10 | Abbott Laboratories | 3-quinuclidinyl heteroatom bridged biaryl derivatives |
US20050137398A1 (en) | 2003-12-22 | 2005-06-23 | Jianguo Ji | 3-Quinuclidinyl heteroatom bridged biaryl derivatives |
US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
JP2007516275A (ja) | 2003-12-23 | 2007-06-21 | ファイザー・プロダクツ・インク | 認知増強および精神病性障害のための治療的組合せ |
RU2377988C2 (ru) | 2004-02-20 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. | Модуляция воспалительных и метастатических процессов |
EP1737852A2 (en) | 2004-04-13 | 2007-01-03 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
JP2007538046A (ja) | 2004-05-19 | 2007-12-27 | ノイロサーチ アクティーゼルスカブ | 新規なアザビシクロアリール誘導体 |
PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
AU2005293510A1 (en) | 2004-10-15 | 2006-04-20 | Neurosearch A/S | Novel azabicyclic aryl derivatives and their medical use |
GB0424564D0 (en) | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
JP2008523058A (ja) | 2004-12-10 | 2008-07-03 | アボット・ラボラトリーズ | 縮合ビシクロ複素環置換キヌクリジン誘導体 |
US7750011B2 (en) | 2005-02-15 | 2010-07-06 | Neurosearch A/S | Diazabicyclic aryl derivatives and their medical use |
EP1863485A2 (en) | 2005-03-18 | 2007-12-12 | Abbott Laboratories | Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions |
EP1907367A4 (en) | 2005-04-18 | 2011-05-11 | Saeed R Khan | DEVELOPMENT AND SYNTHESIS OF NEW TUBULIN POLYMERIZATION INHIBITORS: BENZOYLPHENYL HARVEST (BPU) SULFUR ANALOGUE |
FR2884822B1 (fr) | 2005-04-22 | 2007-06-29 | Aventis Pharma Sa | Derives de triazines, leur preparation et leur application en therapeutique |
GB0508314D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
TWI332005B (en) | 2005-06-14 | 2010-10-21 | Schering Corp | Aspartyl protease inhibitors |
GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
GB0525672D0 (en) * | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
JP5310732B2 (ja) | 2008-10-17 | 2013-10-09 | Nokクリューバー株式会社 | 潤滑グリース組成物およびその製造法 |
-
2002
- 2002-09-04 GB GB0220581A patent/GB0220581D0/en not_active Ceased
-
2003
- 2003-09-03 CA CA 2495685 patent/CA2495685C/en not_active Expired - Lifetime
- 2003-09-03 DK DK03793791T patent/DK1537104T3/da active
- 2003-09-03 WO PCT/EP2003/009772 patent/WO2004022556A1/en active IP Right Grant
- 2003-09-03 CN CNB038207303A patent/CN1325493C/zh not_active Expired - Lifetime
- 2003-09-03 BR BR122014026685-5A patent/BR122014026685B1/pt not_active IP Right Cessation
- 2003-09-03 BR BRPI0314325A patent/BRPI0314325B8/pt active IP Right Grant
- 2003-09-03 EP EP20030793791 patent/EP1537104B1/en not_active Expired - Lifetime
- 2003-09-03 PT PT03793791T patent/PT1537104E/pt unknown
- 2003-09-03 PL PL374013A patent/PL209425B1/pl unknown
- 2003-09-03 JP JP2004533455A patent/JP4348422B2/ja not_active Expired - Lifetime
- 2003-09-03 AU AU2003260486A patent/AU2003260486C1/en not_active Expired
- 2003-09-03 US US10/526,759 patent/US20060167002A1/en not_active Abandoned
- 2003-09-03 ES ES03793791T patent/ES2336099T3/es not_active Expired - Lifetime
- 2003-09-03 EP EP20100184187 patent/EP2308876A1/en not_active Withdrawn
- 2003-09-03 SI SI200331746T patent/SI1537104T1/sl unknown
- 2003-09-03 NZ NZ538534A patent/NZ538534A/en not_active IP Right Cessation
- 2003-09-03 MX MXPA05002546A patent/MXPA05002546A/es active IP Right Grant
- 2003-09-03 KR KR1020077011698A patent/KR20070058027A/ko not_active Application Discontinuation
- 2003-09-03 KR KR20057003665A patent/KR100808324B1/ko active IP Right Review Request
- 2003-09-03 RU RU2005109913A patent/RU2352569C2/ru active
- 2003-09-03 AT AT03793791T patent/ATE448225T1/de active
- 2003-09-03 EP EP20090164576 patent/EP2100893A1/en not_active Withdrawn
- 2003-09-03 DE DE60330015T patent/DE60330015D1/de not_active Expired - Lifetime
-
2005
- 2005-01-27 ZA ZA200500816A patent/ZA200500816B/xx unknown
- 2005-02-15 IL IL16691805A patent/IL166918A/en active IP Right Grant
- 2005-02-22 EC ECSP055621 patent/ECSP055621A/es unknown
- 2005-04-01 NO NO20051626A patent/NO331556B1/no not_active IP Right Cessation
- 2005-11-07 HK HK05109896A patent/HK1077822A1/xx not_active IP Right Cessation
- 2005-11-30 HK HK05110918A patent/HK1078868A1/xx not_active IP Right Cessation
-
2007
- 2007-06-26 US US11/823,312 patent/US7579362B2/en not_active Expired - Lifetime
-
2008
- 2008-10-31 US US12/262,896 patent/US8236803B2/en not_active Expired - Lifetime
-
2009
- 2009-02-19 JP JP2009036918A patent/JP5124714B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-10 CY CY101100129T patent/CY1109765T1/el unknown
-
2012
- 2012-05-02 US US13/462,187 patent/US9012451B2/en not_active Expired - Lifetime
-
2013
- 2013-02-28 IL IL225002A patent/IL225002A/en active IP Right Grant
-
2015
- 2015-03-10 US US14/643,275 patent/US9567343B2/en not_active Expired - Lifetime
-
2017
- 2017-01-04 US US15/398,427 patent/US9849117B2/en not_active Expired - Lifetime
- 2017-11-21 US US15/819,535 patent/US20180078536A1/en not_active Abandoned
-
2018
- 2018-11-15 US US16/191,693 patent/US20190083474A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060821A1 (en) * | 2000-02-18 | 2001-08-23 | Astrazeneca Ab | Novel biarylcarboxamides |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100808324B1 (ko) | 아자-비시클로알킬 에테르 및 이들의 알파7-nAChR 효능제로서의 용도 | |
US6392045B1 (en) | 9-azobicyclo[3.3.1] non-2-ene derivatives as cholinergic ligands at nicotinic ACH receptors | |
KR20140040774A (ko) | 이미다조피리딘 화합물 | |
AU2001262257A1 (en) | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | |
EP1282620A1 (en) | Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists | |
JP2006507241A (ja) | ニコチン性アセチルコリン作用剤としてのビアリールジアザビシクロアルカンアミド | |
NZ561794A (en) | Furyl spiroazabicyclic heterocyclic amines as nicotinic acetylcholine agonists | |
EP2825538B1 (en) | Positive allosteric modulators of mglur2 | |
TW202003496A (zh) | 一種新穎磷酸肌醇3 - 激酶抑制劑及其製備方法和用途 | |
TW201902900A (zh) | 用於誘發軟骨生成之化合物及組合物 | |
JP2001517668A (ja) | N−5,6,7,8−テトラヒドロ(1、6)ナフチリジン−n’−フェニルウレア誘導体 | |
TW202017927A (zh) | 作爲RET激酶抑制劑的取代的[1,2,4]三唑[1,5-a]吡啶化合物 | |
NZ722157B2 (en) | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J202 | Request for trial for correction [limitation] | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20090116 Effective date: 20090226 |
|
FPAY | Annual fee payment |
Payment date: 20130201 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140204 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150120 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160205 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180207 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20200213 Year of fee payment: 13 |